Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2343 May 2025

APPLICANT (stamp or sticker acceptable)				sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg No:					First Names:	First Names:	
Name:					Surname:	Surname:	
Address:					DOB:	Address:	
					Address:		
Fax Number:						Fax Number:	
Ribociclib							
Initial application Applications from any relevant practitioner. Approvals valid for 6 months. Prerequisites(tick boxes where appropriate)							
		and		Patient has unresectable lo	cally advanced or metastatic breast cancer		
				There is documentation cor	firming disease is hormone-receptor positive and HE	R2-negative	
and Patient has an ECOG performance score of 0-2							
		and		Disease has relapsed or progressed during prior endocrine therapy			
			or	Disease has relapsed	or progressed during prior endocrine therapy		
					norrhoeic, either naturally or induced, with endocrine I ual-potential state	evels consistent with a postmenopausal or	
				and		astatic disease	
			or	Patient has not received prior systemic endocrine treatment for metastatic disease			
				Patient commenced treatment with ribociclib in combination with an endocrine partner prior to 1 July 2024			
				and There is no evidence	dence of progressive disease		
		and					
			Treatment to be used in combination with an endocrine partner				
		and [Patient has not received prior funded treatment with a CDK4/6 inhibitor			
	or						
		and		Patient has an active Specia	al Authority approval for palbociclib		
		[Patient has experienced a grade 3 or 4 adverse reaction to palbociclib that cannot be managed by dose reductions and requires reatment discontinuation			
		and [Treatment must be used in	combination with an endocrine partner		
		and		There is no evidence of pro	gressive disease since initiation of palbociclib		
				·	·		
Renewal							
Current approval Number (if known):							
Applications from any relevant practitioner. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)							
Treatment must be used in combination with an endocrine partner							
	and There is no evidence of progressive disease since initiation of ribociclib						

I confirm the above details are correct and that in signing this form I understand I may be audited.